메뉴 건너뛰기




Volumn 123, Issue 10, 2014, Pages 1544-1551

JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes

Author keywords

[No Author keywords available]

Indexed keywords

CALRETICULIN; ERYTHROPOIETIN; HEMOGLOBIN; JANUS KINASE 2; LACTATE DEHYDROGENASE;

EID: 84897517940     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-11-539098     Document Type: Article
Times cited : (493)

References (38)
  • 4
    • 84857893209 scopus 로고    scopus 로고
    • Genetic and epigenetic complexity in myeloproliferative neoplasms
    • Cross NC. Genetic and epigenetic complexity in myeloproliferative neoplasms. Hematology Am Soc Hematol Educ Program. 2011;2011:208-214.
    • (2011) Hematology Am Soc Hematol Educ Program , vol.2011 , pp. 208-214
    • Cross, N.C.1
  • 5
    • 79551607979 scopus 로고    scopus 로고
    • Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations
    • Passamonti F, Elena C, Schnittger S, et al. Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. Blood. 2011;117(10):2813-2816.
    • (2011) Blood , vol.117 , Issue.10 , pp. 2813-2816
    • Passamonti, F.1    Elena, C.2    Schnittger, S.3
  • 6
    • 84880595307 scopus 로고    scopus 로고
    • Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative. Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms
    • Rumi E, Pietra D, Guglielmelli P, et al; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative. Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms. Blood. 2013;121(21):4388-4395.
    • (2013) Blood , vol.121 , Issue.21 , pp. 4388-4395
    • Rumi, E.1    Pietra, D.2    Guglielmelli, P.3
  • 7
    • 84890372480 scopus 로고    scopus 로고
    • Somatic mutations of calreticulin in myeloproliferative neoplasms
    • Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369(25):2379- 2390.
    • (2013) N Engl J Med , vol.369 , Issue.25 , pp. 2379-2390
    • Klampfl, T.1    Gisslinger, H.2    Harutyunyan, A.S.3
  • 8
    • 84890328032 scopus 로고    scopus 로고
    • Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2
    • Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369(25):2391-2405.
    • (2013) N Engl J Med , vol.369 , Issue.25 , pp. 2391-2405
    • Nangalia, J.1    Massie, C.E.2    Baxter, E.J.3
  • 10
    • 33646406275 scopus 로고    scopus 로고
    • Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders
    • Passamonti F, Rumi E, Pietra D, et al. Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. Blood. 2006;107(9):3676-3682.
    • (2006) Blood , vol.107 , Issue.9 , pp. 3676-3682
    • Passamonti, F.1    Rumi, E.2    Pietra, D.3
  • 11
    • 33749358349 scopus 로고    scopus 로고
    • Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia
    • DOI 10.1182/blood-2006-04-018259
    • Scott LM, Scott MA, Campbell PJ, Green AR. Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia. Blood. 2006;108(7):2435-2437. (Pubitemid 44497530)
    • (2006) Blood , vol.108 , Issue.7 , pp. 2435-2437
    • Scott, L.M.1    Scott, M.A.2    Campbell, P.J.3    Green, A.R.4
  • 12
    • 84866633441 scopus 로고    scopus 로고
    • JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone
    • Godfrey AL, Chen E, Pagano F, et al. JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone. Blood. 2012;120(13):2704-2707.
    • (2012) Blood , vol.120 , Issue.13 , pp. 2704-2707
    • Godfrey, A.L.1    Chen, E.2    Pagano, F.3
  • 13
    • 43249084493 scopus 로고    scopus 로고
    • Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice
    • Tiedt R, Hao-Shen H, Sobas MA, et al. Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood. 2008;111(8):3931-3940.
    • (2008) Blood , vol.111 , Issue.8 , pp. 3931-3940
    • Tiedt, R.1    Hao-Shen, H.2    Sobas, M.A.3
  • 15
    • 0036786901 scopus 로고    scopus 로고
    • The World Health Organization (WHO) classification of the myeloid neoplasms
    • Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100(7):2292-2302.
    • (2002) Blood , vol.100 , Issue.7 , pp. 2292-2302
    • Vardiman, J.W.1    Harris, N.L.2    Brunning, R.D.3
  • 17
    • 84871746842 scopus 로고    scopus 로고
    • Cardiovascular events and intensity of treatment in polycythemia vera
    • CYTO-PV Collaborative Group
    • Marchioli R, Finazzi G, Specchia G, et al CYTO-PV Collaborative Group. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013;368(1):22-33.
    • (2013) N Engl J Med , vol.368 , Issue.1 , pp. 22-33
    • Marchioli, R.1    Finazzi, G.2    Specchia, G.3
  • 18
    • 24944524079 scopus 로고    scopus 로고
    • European consensus on grading bone marrow fibrosis and assessment of cellularity
    • Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica. 2005;90(8):1128-1132. (Pubitemid 41323513)
    • (2005) Haematologica , vol.90 , Issue.8 , pp. 1128-1132
    • Thiele, J.1    Kvasnicka, H.M.2    Facchetti, F.3    Franco, V.4    Van Der, W.J.5    Orazi, A.6
  • 20
    • 34548152255 scopus 로고    scopus 로고
    • Amendment to the guideline for diagnosis and investigation of polycythaemia/erythrocytosis [6]
    • DOI 10.1111/j.1365-2141.2007.06741.x
    • McMullin MF, Reilly JT, Campbell P, et al National Cancer Research Institute, Myeloproliferative Disorder Subgroup; British Committee for Standards in Haematology. Amendment to the guideline for diagnosis and investigation of polycythaemia/erythrocytosis. Br J Haematol. 2007;138(6):821-822. (Pubitemid 47313223)
    • (2007) British Journal of Haematology , vol.138 , Issue.6 , pp. 821-822
    • McMullin, M.F.1    Reilly, J.T.2    Campbell, P.3    Bareford, D.4    Green, A.R.5    Harrison, C.N.6    Conneally, E.7    Ryan, K.8
  • 21
    • 70449486011 scopus 로고    scopus 로고
    • Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis
    • Malcovati L, Della Porta MG, Pietra D, et al. Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Blood. 2009;114(17):3538-3545.
    • (2009) Blood , vol.114 , Issue.17 , pp. 3538-3545
    • Malcovati, L.1    Della Porta, M.G.2    Pietra, D.3
  • 23
    • 79953890796 scopus 로고    scopus 로고
    • Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms
    • Pietra D, Brisci A, Rumi E, et al. Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms. Haematologica. 2011;96(4):607-611.
    • (2011) Haematologica , vol.96 , Issue.4 , pp. 607-611
    • Pietra, D.1    Brisci, A.2    Rumi, E.3
  • 24
    • 0018080123 scopus 로고
    • The analysis of failure times in the presence of competing risks
    • Prentice RL, Kalbfleisch JD, Peterson AV Jr, Flournoy N, Farewell VT, Breslow NE. The analysis of failure times in the presence of competing risks. Biometrics. 1978;34(4):541-554. (Pubitemid 9067879)
    • (1978) Biometrics , vol.34 , Issue.4 , pp. 541-554
    • Prentice, R.L.1    Kalbfleisch, J.D.2    Peterson, A.V.3
  • 25
    • 0027166881 scopus 로고
    • Kaplan-Meier, marginal or conditional probability curves in summarizing competing risks failure time data?
    • Pepe MS, Mori M. Kaplan-Meier, marginal or conditional probability curves in summarizing competing risks failure time data? Stat Med. 1993;12(8):737-751. (Pubitemid 23134304)
    • (1993) Statistics in Medicine , vol.12 , Issue.8 , pp. 737-751
    • Pepe, M.S.1    Mori, M.2
  • 26
    • 1542532754 scopus 로고    scopus 로고
    • A proportional hazards model for the subdistribution of a competing risk
    • Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496-509.
    • (1999) J Am Stat Assoc , vol.94 , Issue.446 , pp. 496-509
    • Fine, J.P.1    Gray, R.J.2
  • 27
    • 79551491928 scopus 로고    scopus 로고
    • European LeukemiaNet. Philadelphia-negative classical myeloproliferative neoplasms: Critical concepts and management recommendations from European LeukemiaNet
    • Barbui T, Barosi G, Birgegard G, et al; European LeukemiaNet. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011;29(6):761-770.
    • (2011) J Clin Oncol , vol.29 , Issue.6 , pp. 761-770
    • Barbui, T.1    Barosi, G.2    Birgegard, G.3
  • 28
    • 84865187605 scopus 로고    scopus 로고
    • A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: A study by the International Working Group on Myelofibrosis Research and Treatment
    • Passamonti F, Thiele J, Girodon F, et al. A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment. Blood. 2012;120(6):1197-1201.
    • (2012) Blood , vol.120 , Issue.6 , pp. 1197-1201
    • Passamonti, F.1    Thiele, J.2    Girodon, F.3
  • 29
    • 84871501896 scopus 로고    scopus 로고
    • Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis)
    • CME questions 5252
    • Barbui T, Finazzi G, Carobbio A, et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood. 2012;120(26):5128-5133; CME questions 5252.
    • (2012) Blood , vol.120 , Issue.26 , pp. 5128-5133
    • Barbui, T.1    Finazzi, G.2    Carobbio, A.3
  • 30
    • 84878232331 scopus 로고    scopus 로고
    • JAK/STAT signaling in hematological malignancies
    • Vainchenker W, Constantinescu SN. JAK/STAT signaling in hematological malignancies. Oncogene. 2013;32(21):2601-2613.
    • (2013) Oncogene , vol.32 , Issue.21 , pp. 2601-2613
    • Vainchenker, W.1    Constantinescu, S.N.2
  • 31
    • 77956439565 scopus 로고    scopus 로고
    • A prospective study of 338 patients with polycythemia vera: The impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications
    • Passamonti F, Rumi E, Pietra D, et al. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia. 2010;24(9):1574-1579.
    • (2010) Leukemia , vol.24 , Issue.9 , pp. 1574-1579
    • Passamonti, F.1    Rumi, E.2    Pietra, D.3
  • 32
    • 32144461605 scopus 로고    scopus 로고
    • Essential thrombocythemia beyond the first decade: Life expectancy, long-term complication rates, and prognostic factors
    • Wolanskyj AP, Schwager SM, McClure RF, Larson DR, Tefferi A. Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc. 2006;81(2):159-166. (Pubitemid 43205767)
    • (2006) Mayo Clinic Proceedings , vol.81 , Issue.2 , pp. 159-166
    • Wolanskyj, A.P.1    Schwager, S.M.2    McClure, R.F.3    Larson, D.R.4    Tefferi, A.5
  • 33
    • 84865193045 scopus 로고    scopus 로고
    • Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: A population-based study
    • Hultcrantz M, Kristinsson SY, Andersson TM, et al. Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study. J Clin Oncol. 2012;30(24):2995-3001.
    • (2012) J Clin Oncol , vol.30 , Issue.24 , pp. 2995-3001
    • Hultcrantz, M.1    Kristinsson, S.Y.2    Andersson, T.M.3
  • 35
    • 78249256979 scopus 로고    scopus 로고
    • Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling
    • Chen E, Beer PA, Godfrey AL, et al. Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling. Cancer Cell. 2010;18(5):524-535.
    • (2010) Cancer Cell , vol.18 , Issue.5 , pp. 524-535
    • Chen, E.1    Beer, P.A.2    Godfrey, A.L.3
  • 37
    • 79957975519 scopus 로고    scopus 로고
    • Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: An international study of 891 patients
    • Carobbio A, Thiele J, Passamonti F, et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood. 2011;117(22):5857-5859.
    • (2011) Blood , vol.117 , Issue.22 , pp. 5857-5859
    • Carobbio, A.1    Thiele, J.2    Passamonti, F.3
  • 38
    • 33644501833 scopus 로고    scopus 로고
    • Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status
    • Arellano-Rodrigo E, Alvarez-Larrán A, Reverter JC, Villamor N, Colomer D, Cervantes F. Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. Haematologica. 2006;91(2):169-175.
    • (2006) Haematologica , vol.91 , Issue.2 , pp. 169-175
    • Arellano-Rodrigo, E.1    Alvarez-Larrán, A.2    Reverter, J.C.3    Villamor, N.4    Colomer, D.5    Cervantes, F.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.